全球精选文摘 - 针对局部进展期直肠癌的两种新辅助放化疗方案的比较：ACCORD 12/0405-Prodige 2 Ⅲ期试验的结果

内容预览：Purpose: Neoadjuvant chemoradiotherapy is considered a standard approach for T3-4 M0 rectal cancer. In this situation, we compared neoadjuvant radiotherapy plus capecitabine with dose-intensified radiotherapy plus capecitabine and oxaliplatin. Patients and Methods: We randomly assigned patients to receive 5weeks of treatment with radiotherapy 45Gy/25 fractions with concurrent capecitabine 800mg/m2 twice daily 5days per week (Cap 45) or radiotherapy 50Gy/25 fractions with capecitabine 800mg/m2 twice daily 5days per week and oxaliplatin 50mg/m2 once weekly (Capox 50). The primary end point was complete sterilization of the operative specimen (ypCR). Results: Five hundred ninety-eight patients were randomly assigned to receive Cap 45 (n=299) or Capox 50 (n=299). More preoperative grade 3...

请登录后阅读全文

会员登录

非会员注册登录

如您已是注册会员，请即刻登录浏览。

用户名：
密码：
	下次自动登录
	忘记密码?

欢迎您访问全球最大医学信息传媒集团Elsevier旗下的ElsevierMed中国医学网！

如您尚未注册，我们诚邀您即刻进行免费注册，注册后您将可以访问站内所有栏目的全文内容。我们还会定期为您发送适合您的电子新闻和各种丰富线下活动信息。

即刻免费注册登录

医学数据库